ALIM - Alimera Sciences Inc Stock Price, Fair Value and News

3.71USD+0.04 (+1.09%)Market Closed

Market Summary

USD3.71+0.04

Market Closed

1.09%

ALIM Stock Price

View Fullscreen

ALIM RSI Chart

ALIM Valuation

Market Cap

194.3M

Price/Earnings (Trailing)

-9.65

Price/Sales (Trailing)

2.41

EV/EBITDA

2.5K

Price/Free Cashflow

-13.38

ALIM Price/Sales (Trailing)

ALIM Profitability

EBT Margin

-23.35%

Return on Equity

-43.6%

Return on Assets

-13.11%

Free Cashflow Yield

-7.47%

ALIM Fundamentals

ALIM Revenue

Revenue (TTM)

80.8M

Rev. Growth (Yr)

87.51%

Rev. Growth (Qtr)

12.59%

ALIM Earnings

Earnings (TTM)

-20.1M

Earnings Growth (Yr)

-0.03%

Earnings Growth (Qtr)

-179.25%

Breaking Down ALIM Revenue

Last 7 days

3.3%

Last 30 days

-4.9%

Last 90 days

1.6%

Trailing 12 Months

109.6%

How does ALIM drawdown profile look like?

ALIM Financial Health

Current Ratio

2.39

ALIM Investor Care

Shares Dilution (1Y)

607.30%

Diluted EPS (TTM)

-1.33

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	55.8M	58.7M	68.5M	80.8M
2022	59.7M	52.6M	54.1M	54.1M
2021	47.5M	59.2M	58.8M	59.0M
2020	55.6M	54.8M	54.4M	50.8M
2019	49.9M	50.0M	51.7M	53.9M
2018	38.9M	39.3M	40.6M	46.6M
2017	35.1M	36.0M	37.4M	35.9M
2016	24.3M	28.1M	29.5M	34.3M
2015	10.3M	13.9M	18.4M	22.4M
2014	3.5M	5.1M	6.8M	8.4M
2013	0	0	0	1.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Alimera Sciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 26, 2024	ashman philip	sold (taxes)	-46,354	3.83	-12,103	president of int'l operations
Jan 10, 2024	ashman philip	sold (taxes)	-11,343	3.861	-2,938	president of int'l operations
Oct 02, 2023	eiswirth richard s jr	acquired	-	-	400,000	president and ceo
Oct 02, 2023	werner jason m.	acquired	-	-	225,000	chief operating officer
Sep 14, 2023	caligan partners lp	bought	1,962,810	3.39	579,000	-
Sep 14, 2023	caligan partners lp	sold	-1,962,810	3.39	-579,000	-
Aug 15, 2023	caligan partners lp	acquired	6,142,000	2.1	2,924,760	-
Aug 15, 2023	morgan adam	acquired	14,379,200	1.85056	7,770,150	-
Aug 15, 2023	caligan partners lp	acquired	22,833,700	1.7	13,431,600	-
Aug 15, 2023	morgan adam	acquired	7,103,830	1.7	4,178,720	-

Which funds bought or sold ALIM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 21, 2024	HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	sold off	-100	-775,000	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	342	2,348,760	2,803,480	-%
Feb 15, 2024	BARCLAYS PLC	sold off	-100	-	-	-%
Feb 14, 2024	Clearline Capital LP	reduced	-7.11	2,131,290	9,370,700	0.57%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	85,856	85,856	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-51.11	-	-	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	24,400	86,400	-%
Feb 14, 2024	Balyasny Asset Management L.P.	new	-	172,938	172,938	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-63.86	-138,182	140,232	-%

Are Funds Buying or Selling ALIM?

Are funds buying ALIM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALIM

No. of Funds

Unveiling Alimera Sciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	lytton laurence w	4.2%	2,185,364	SC 13G/A
Feb 13, 2024	altium capital management lp	5.0%	2,660,000	SC 13G/A
Feb 13, 2024	boothbay fund management, llc	6.1%	3,198,708	SC 13G/A
Feb 13, 2024	stonepine capital management, llc	9.99%	5,373,732	SC 13G/A
Feb 13, 2024	hbm healthcare investments (cayman) ltd.	0.9%	466,666	SC 13G/A
Dec 08, 2023	morgan stanley	1.8%	916,246	SC 13G/A
Aug 23, 2023	altium capital management lp	5.7%	2,984,803	SC 13G
Aug 16, 2023	velan capital investment management lp	18.0%	9,429,808	SC 13D/A
Aug 14, 2023	lytton laurence w	5.7%	2,984,803	SC 13G
Aug 10, 2023	boothbay fund management, llc	8.99%	4,784,480	SC 13G

Recent SEC filings of Alimera Sciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	10-K/A	Annual Report
Apr 02, 2024	4	Insider Trading
Mar 13, 2024	4	Insider Trading
Mar 13, 2024	4	Insider Trading
Mar 13, 2024	4	Insider Trading
Mar 13, 2024	4	Insider Trading
Mar 13, 2024	4	Insider Trading
Mar 08, 2024	S-8	Employee Benefits Plan
Mar 08, 2024	10-K	Annual Report
Mar 07, 2024	8-K	Current Report

Peers (Alternatives to Alimera Sciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	348.3B	85.2B	-8.60%	-11.62%	9.91	4.09	6.46%	95.94%
MRK	327.3B	60.1B	-2.07%	11.07%	896.63	5.44	1.40%	-97.49%
AMGN	146.8B	28.2B	-3.65%	14.67%	21.86	5.21	7.09%	2.52%
PFE	144.7B	46.5B	-7.68%	-34.66%	-104.19	3.11	42.59%	-114.62%
GILD	81.2B	27.1B	-10.99%	-19.92%	14.34	3	-0.60%	23.36%
TEVA	15.7B	15.8B	-0.43%	58.94%	-27.32	0.99	6.17%	76.47%
MID-CAP
PRGO	4.4B	4.7B	1.46%	-13.00%	-348.5	0.95	4.58%	90.97%
ALKS	4.1B	1.7B	-9.35%	-14.32%	11.52	2.46	49.61%	324.78%
BHC	3.2B	8.8B	-17.44%	16.64%	-5.41	0.37	7.79%	-163.11%
AMPH	2.0B	644.4M	-6.06%	10.65%	14.42	3.08	29.14%	50.51%
SMALL-CAP
TLRY	1.9B	743.2M	-	8.33%	-5.43	2.57	24.65%	80.36%
TXMD	21.7M	1.3M	-17.90%	-45.03%	-2.11	16.65	-98.14%	-109.18%
ACRX	17.3M	-	-0.97%	54.22%	-0.94	0.22	2882.68%	-138.52%
AGRX	2.9M	19.6M	29.41%	-93.03%	-0.2	0.15	80.00%	43.08%
ACOR	1.1M	117.6M	-93.87%	-92.27%	0	0.01	-0.79%	-283.60%

Alimera Sciences Inc News

Latest updates

Alimera Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	12.6%	26,306	23,364	17,538	13,546	14,029	13,598	14,604	11,898	13,959	12,153	21,703	11,214	13,774	12,473	10,038	14,535	17,348	12,850	10,855	12,890	15,115
Gross Profit	10.1%	22,680	20,606	15,113	11,518	11,904	11,592	12,438	10,218	11,993	10,464	19,890	9,652	11,782	10,936	8,553	12,608	15,075	11,271	9,681	11,290	13,789
Operating Expenses	17.1%	21,956	18,752	16,321	14,820	14,012	15,003	14,412	14,365	14,745	12,486	12,887	12,082	11,609	10,529	9,852	12,390	13,648	12,987	13,271	12,685	13,717
S&GA Expenses	-2.2%	7,768	7,940	6,434	5,804	5,765	6,504	6,865	6,853	7,169	5,751	5,331	4,818	4,986	4,962	4,566	5,870	8,489	6,437	6,108	3,393	3,995
R&D Expenses	17.9%	4,769	4,045	3,648	4,164	4,230	4,483	3,932	3,583	3,720	3,278	3,567	3,213	2,506	2,469	1,810	2,883	2,670	2,761	2,834	2,727	2,876
EBITDA Margin	100.9%	0.00*	-0.10*	-0.20*	-0.13*	-0.14*	-0.16*	0.09*	0.07*	0.07*	0.12*	0.18*	0.00*	0.05*	-	-	-	-	-	-	-	-
Interest Expenses	129.7%	4,754	2,070	1,694	1,667	1,634	1,500	1,383	1,364	1,363	1,360	1,347	1,343	1,452	1,285	1,351	1,292	1,173	1,232	1,236	1,228	1,235
Income Taxes	-86.8%	7.00	53.00	25.00	-	-10.00	12.00	17.00	18.00	-35.00	-169	640	4.00	-123	7.00	5.00	43.00	-193	77.00	261	71.00	2.00
Earnings Before Taxes	-190.1%	-3,774	-1,301	-10,004	-	-3,781	-5,245	-3,098	-	-4,139	-4,352	8,205	-3,648	-1,100	-611	-2,541	-1,155	305	-3,063	-4,777	-2,692	-1,246
EBT Margin	21.3%	-0.23*	-0.30*	-0.38*	-0.29*	-0.30*	-0.31*	-0.06*	-0.07*	-0.07*	-0.02*	0.05*	-0.17*	-0.11*	-	-	-	-	-	-	-	-
Net Income	-179.2%	-3,781	-1,354	-10,029	-4,968	-3,780	-5,257	-3,115	-5,955	-4,106	-4,183	7,565	-3,648	-977	-618	-2,546	-1,198	498	-3,140	-5,038	-2,763	-1,248
Net Income Margin	15.2%	-0.25*	-0.29*	-0.41*	-0.31*	-0.33*	-0.34*	-0.33*	-0.11*	-0.07*	-0.02*	0.04*	-0.16*	-0.11*	-	-	-	-	-	-	-	-
Free Cashflow	137.5%	3,685	-9,830	-6,158	-2,218	-335	-2,043	-1,490	-6,362	-4,804	-3,042	6,586	-2,585	-348	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-0.4%	154	154	155	48.00	43.00	43.00	48.00	50.00	59.00	60.00	62.00	46.00	51.00	49.00	49.00	49.00	50.00	47.00	50.00	52.00	54.00
Current Assets	8.3%	52.00	48.00	46.00	36.00	29.00	30.00	33.00	35.00	42.00	44.00	45.00	30.00	35.00	33.00	32.00	32.00	33.00	28.00	31.00	33.00	35.00
Cash Equivalents	45.5%	12.00	8.00	19.00	13.00	5.00	6.00	8.00	10.00	17.00	22.00	25.00	8.00	11.00	11.00	14.00	12.00	9.00	8.00	12.00	13.00	13.00
Inventory	6.8%	2.00	2.00	1.00	1.00	2.00	2.00	2.00	2.00	3.00	2.00	2.00	3.00	3.00	3.00	2.00	1.00	1.00	2.00	2.00	2.00	2.00
Net PPE	1.0%	2.00	2.00	2.00	2.00	3.00	2.00	2.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-	107	-	-	-	63.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	23.7%	22.00	18.00	14.00	14.00	40.00	34.00	25.00	17.00	13.00	11.00	10.00	11.00	12.00	10.00	10.00	9.00	12.00	14.00	12.00	10.00	10.00
Shareholder's Equity	-5.5%	46.00	49.00	46.00	-	-20.81	-	-	-	-2.60	2.00	6.00	-	-	-	-	-	-	-	-	1.00	3.00
Retained Earnings	-0.9%	-418	-414	-412	-402	-415	-411	-406	-403	-397	-393	-388	-396	-392	-391	-391	-388	-387	-388	-384	-379	-377
Additional Paid-In Capital	0.2%	462	462	387	378	378	378	378	378	377	377	376	366	366	353	351	350	350	348	348	347	347
Shares Outstanding	-0.1%	52.00	52.00	9.00	7.00	7.00	7.00	7.00	7.00	7.00	6.00	7.00	6.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	14.00	-	-	-	31.00	-	-	-	60.00	-	-	-	30.00	-	-	-	60.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	138.4%	3,770	-9,826	-5,996	-2,209	-251	-1,913	-1,598	-6,213	-4,683	-2,732	6,692	-2,501	-263	-2,148	-330	548	422	-3,898	-960	284	660
Share Based Compensation	1354.8%	902	62.00	148	226	304	134	43.00	312	364	23.00	224	262	424	22.00	279	440	-1,711	504	629	770	-2,873
Cashflow From Investing	-2025.0%	-85.00	-4.00	-75,434	-9.00	-84.00	-130	108	-149	-121	-310	-106	-84.00	-85.00	-318	-192	-25.00	-24.00	-111	-24.00	-15.00	-1.00
Cashflow From Financing	85.7%	-78.00	-546	87,125	9,998	-193	55.00	-102	-62.00	-19.00	-49.00	9,948	-57.00	-46.00	-110	1,623	2,415	1,069	-58.00	-32.00	-110	-25.00
Buy Backs	-	-	-	-624	938	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ALIM Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Consolidated Statements of Operations [Abstract]
Net revenue	$ 80,754	$ 54,129
Cost of goods sold, excluding depreciation and amortization	(10,837)	(7,977)
Gross profit	69,917	46,152
Operating expenses:
Research, development and medical affairs expenses	16,626	16,228
General and administrative expenses	18,530	12,871
Sales and marketing expenses	27,946	25,987
Depreciation and amortization	8,747	2,706
Total operating expenses	71,849	57,792
Loss from operations	(1,932)	(11,640)
Interest expense and other, net	(10,185)	(5,881)
Unrealized foreign currency gain, net	116	92
Loss on extinguishment of debt	(1,079)
Change in fair value of common stock warrant	(6,836)
Change in fair value of warrant asset	(131)	(650)
Net loss before income taxes	(20,047)	(18,079)
Income tax provision	(85)	(28)
Net loss	(20,132)	(18,107)
Preferred stock dividends	(1,259)
Net loss applicable to common stockholders	$ (21,391)	$ (18,107)
Net loss per share — basic	$ (0.84)	$ (2.59)
Net loss per share — diluted	$ (0.84)	$ (2.59)
Weighted average shares outstanding — Basic	25,561,885	6,996,850
Weighted average shares outstanding — Diluted	25,561,885	6,996,850

ALIM Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 12,058	$ 5,274
Restricted cash	32	30
Accounts receivable, net	34,545	19,612
Prepaid expenses and other current assets	3,909	2,892
Inventory	1,879	1,605
Total current assets	52,423	29,413
Property and equipment, net	2,466	2,525
Right of use assets, net	1,124	1,395
Intangible asset, net	97,355	8,957
Deferred tax asset	104	129
Warrant asset	52	183
Total assets	153,524	42,602
Current liabilities:
Accounts payable	8,252	10,088
Accrued expenses	6,192	3,998
Accrued licensor payments	7,275
Notes payable		25,313
Finance lease obligations	194	333
Total current liabilities	21,913	39,732
Notes payable	64,489	18,683
Accrued licensor payments	15,136
Other non-current liabilities	5,816	4,995
Total liabilities	107,354	63,410
Commitments and contingencies (Note 15)
Stockholders’ equity (deficit):
Common stock, $.01 par value - 150,000,000 shares authorized, 52,354,450 shares issued and outstanding at December 31, 2023 and 6,995,513 issued and outstanding at December 31, 2022	524	70
Common stock warrants	4,396
Additional paid-in capital	462,446	378,238
Accumulated deficit	(418,490)	(415,388)
Accumulated other comprehensive loss — foreign currency translation adjustments	(2,706)	(2,955)
Total Stockholders’ equity (deficit)	46,170	(20,808)
Total liabilities and stockholders’ equity (deficit)	$ 153,524	42,602
Series A Preferred Stock [Member]
Stockholders’ equity (deficit):
Preferred stock, $.01 par value — 10,000,000 shares authorized at December 31, 2023 and 2022: Series A Convertible Preferred Stock, 0 and 1,300,000 authorized at December 31, 2023 and 2022, 0 and 600,000 issued and outstanding at December 31, 2023 and 2022; liquidation preference of $0 and $24,000 at December 31, 2023 and 2022		$ 19,227

About Alimera Sciences Inc

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, clinics, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

CEO	Mr. Richard S. Eiswirth Jr.
WEBSITE	https://alimerasciences.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	150

Alimera Sciences Inc Frequently Asked Questions

What is the ticker symbol for Alimera Sciences Inc? What does ALIM stand for in stocks?

ALIM is the stock ticker symbol of Alimera Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alimera Sciences Inc (ALIM)?

As of Tue Apr 30 2024, market cap of Alimera Sciences Inc is 194.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALIM stock?

You can check ALIM's fair value in chart for subscribers.

What is the fair value of ALIM stock?

You can check ALIM's fair value in chart for subscribers. The fair value of Alimera Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Alimera Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALIM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Alimera Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether ALIM is over valued or under valued. Whether Alimera Sciences Inc is cheap or expensive depends on the assumptions which impact Alimera Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALIM.

What is Alimera Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, ALIM's PE ratio (Price to Earnings) is -9.65 and Price to Sales (PS) ratio is 2.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALIM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Alimera Sciences Inc's stock?

In the past 10 years, Alimera Sciences Inc has provided -0.272 (multiply by 100 for percentage) rate of return.